Gena Wang
Stock Analyst at Barclays
(2.22)
# 2,679
Out of 4,884 analysts
203
Total ratings
39.55%
Success rate
-3.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Upgrades: Overweight | $51 → $57 | $43.00 | +32.56% | 10 | Jul 1, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $89 → $29 | $18.24 | +58.99% | 10 | Jun 17, 2025 | |
| RNA Avidity Biosciences | Maintains: Overweight | $57 → $59 | $29.17 | +102.26% | 3 | Jun 10, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $15 → $10 | $5.03 | +98.81% | 7 | May 16, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Overweight | $9 → $5 | $0.53 | +848.95% | 4 | May 14, 2025 | |
| CLLS Cellectis | Maintains: Overweight | $5 → $4 | $1.58 | +153.16% | 4 | May 13, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $56 → $42 | $52.17 | -19.49% | 16 | May 9, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Overweight | $45 → $38 | $4.24 | +796.23% | 2 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $56 → $42 | $49.07 | -14.41% | 15 | May 8, 2025 | |
| CYTK Cytokinetics | Maintains: Overweight | $55 → $53 | $34.66 | +52.91% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $11 | $8.94 | +23.04% | 10 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $31 → $25 | $20.01 | +24.94% | 9 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $45 → $40 | $30.49 | +31.19% | 9 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $5.41 | +473.01% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $26 | $10.74 | +142.09% | 7 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $435 → $467 | $459.62 | +1.61% | 17 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $2.57 | +16.73% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $3 → $4 | $3.95 | +1.27% | 8 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $295 → $329 | $331.91 | -0.88% | 7 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $86 | $57.50 | +49.57% | 15 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $50 | $8.74 | +472.08% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $81 | $39.91 | +102.96% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $94 | $35.64 | +163.75% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $13.04 | -30.98% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $13.78 | +81.42% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $7.51 | +139.68% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $3.58 | +151.40% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $5.89 | +4,568.93% | 1 | Jan 6, 2017 |
Ionis Pharmaceuticals
Jul 1, 2025
Upgrades: Overweight
Price Target: $51 → $57
Current: $43.00
Upside: +32.56%
Sarepta Therapeutics
Jun 17, 2025
Maintains: Overweight
Price Target: $89 → $29
Current: $18.24
Upside: +58.99%
Avidity Biosciences
Jun 10, 2025
Maintains: Overweight
Price Target: $57 → $59
Current: $29.17
Upside: +102.26%
Solid Biosciences
May 16, 2025
Maintains: Overweight
Price Target: $15 → $10
Current: $5.03
Upside: +98.81%
Sangamo Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $9 → $5
Current: $0.53
Upside: +848.95%
Cellectis
May 13, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $1.58
Upside: +153.16%
CRISPR Therapeutics AG
May 9, 2025
Maintains: Equal-Weight
Price Target: $56 → $42
Current: $52.17
Upside: -19.49%
4D Molecular Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $45 → $38
Current: $4.24
Upside: +796.23%
PTC Therapeutics
May 8, 2025
Maintains: Equal-Weight
Price Target: $56 → $42
Current: $49.07
Upside: -14.41%
Cytokinetics
May 8, 2025
Maintains: Overweight
Price Target: $55 → $53
Current: $34.66
Upside: +52.91%
May 7, 2025
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $8.94
Upside: +23.04%
May 7, 2025
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $20.01
Upside: +24.94%
May 2, 2025
Maintains: Equal-Weight
Price Target: $45 → $40
Current: $30.49
Upside: +31.19%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $5.41
Upside: +473.01%
Feb 28, 2025
Maintains: Overweight
Price Target: $55 → $26
Current: $10.74
Upside: +142.09%
Feb 11, 2025
Maintains: Equal-Weight
Price Target: $435 → $467
Current: $459.62
Upside: +1.61%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $2.57
Upside: +16.73%
Nov 15, 2024
Maintains: Underweight
Price Target: $3 → $4
Current: $3.95
Upside: +1.27%
Nov 1, 2024
Maintains: Overweight
Price Target: $295 → $329
Current: $331.91
Upside: -0.88%
Oct 4, 2024
Maintains: Overweight
Price Target: $110 → $86
Current: $57.50
Upside: +49.57%
Aug 5, 2024
Maintains: Overweight
Price Target: $55 → $50
Current: $8.74
Upside: +472.08%
Aug 5, 2024
Maintains: Overweight
Price Target: $83 → $81
Current: $39.91
Upside: +102.96%
Jan 24, 2024
Maintains: Overweight
Price Target: $93 → $94
Current: $35.64
Upside: +163.75%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $13.04
Upside: -30.98%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $13.78
Upside: +81.42%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $7.51
Upside: +139.68%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $3.58
Upside: +151.40%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $5.89
Upside: +4,568.93%